Loading
A phase 2 trial of Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin and Cisplatin in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS is a phase 2 interventional study registered as NCT06008093 by AstraZeneca, with 103 participants enrolled, started 2024-04-04 and due to reach its primary completion in 2026-10-23. Interventions recorded: Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin and Cisplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Durvalumab, AstraZeneca, Cisplatin and the tag pipeline.
Shares Tremelimumab, Durvalumab, AstraZeneca, Cisplatin and the tag pipeline.
Shares Tremelimumab, Durvalumab, AstraZeneca, Cisplatin and the tag pipeline.
Shares Tremelimumab, Durvalumab, AstraZeneca, Cisplatin and the tag pipeline.
Shares Pemetrexed, Durvalumab, AstraZeneca, Cisplatin and the tag pipeline.
Shares Tremelimumab, Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/